The Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist.
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2018
Price : $35 *
At a glance
- Drugs Betrixaban (Primary)
- Indications Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Portola Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 05 Feb 2018 Status changed from recruiting to completed.
- 16 Jan 2018 New trial record